These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

873 related articles for article (PubMed ID: 22961666)

  • 1. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
    Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
    PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetic snapshot of small cell lung cancer.
    Rosell R; Wannesson L
    Cancer Discov; 2012 Sep; 2(9):769-71. PubMed ID: 22969115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
    Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
    Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer.
    Postel-Vinay S; Bajrami I; Friboulet L; Elliott R; Fontebasso Y; Dorvault N; Olaussen KA; André F; Soria JC; Lord CJ; Ashworth A
    Oncogene; 2013 Nov; 32(47):5377-87. PubMed ID: 23934192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
    Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Fer N; Sonkin D; Kaur G; Monks A; Malik S; Morris J; Teicher BA
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27247353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways.
    Wan J; Wu W
    J Exp Clin Cancer Res; 2016 Jul; 35(1):119. PubMed ID: 27456341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.
    Du L; Schageman JJ; Irnov ; Girard L; Hammond SM; Minna JD; Gazdar AF; Pertsemlidis A
    J Exp Clin Cancer Res; 2010 Jun; 29(1):75. PubMed ID: 20624269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
    Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
    BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
    BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer.
    Zhang Z; Lian X; Xie W; Quan J; Liao M; Wu Y; Yang ZZ; Wang G
    Sci Rep; 2020 Dec; 10(1):20924. PubMed ID: 33262410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.